DRL launches DRDO drug 2-DG to treat moderate to severe Covid patients

2-DG was developed by the Institute of Nuclear Medicine & Allied Sciences (INMAS), a laboratory of the Defence Research and Development Organisation (DRDO), in collaboration with Dr Reddy's

Dr Reddy's Laboratories (DRL) commercially launched 2-deoxy-D-glucose (2-DG), a drug used for treating Coronavirus (Covid-19) patients, priced at Rs 990 for a sachet. The company said on Monday that it will supply the drug to major government as well as private hospitals across India.

"In the initial weeks, the company will make the drug available in hospitals across metros and tier-1 cities, and subsequently expand coverage to the rest of India. 2-DG, manufactured by Dr Reddy’s, has a purity of 99.5% and is being sold commercially under the brand name 2DGTM," DRL said. The maximum retail price is Rs 990